Romidepsin (FK228, depsipeptide)

Catalog #
27646-1
$195 *
Size: 1 mg
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Romidepsin, also known as FK228 or depsipeptide, is a potent and selective inhibitor of HDAC1 and HDAC2 , which are associated with the regulation of re-expression of silenced tumor suppressor genes. It was the first HDAC inhibitor to manifest anti-tumor activity and originally isolated from a rod-shaped Gram-negative bacterium, Chromobacterium violaceum, found in a Japanese soil sample. Romidepsin exhibits a stronger inhibition towards HDAC1 and HDAC2 enzymes (class I), removing acetyl groups from the lysine residues of N-terminal histone tails and maintaining a more open and transcriptionally active chromatin state, than HDAC4 and HDAC6 enzymes (class II). Besides HDAC inhibition, romidepsin is also able to induce cell cycle arrest, cellular differentiation, apoptosis and alteration of gene expression in adult malignancies.

Synonyms
Istodax; FK228; FR 901228, FK-228; Romidepsin; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
Product Info
Storage and Usage
Citations
Purity

≥98% by HPLC

Target(s)
HDAC
Formula
C24H36N4O6S2
MW
540.7 Da
Solubility
Soluble in DMSO
Biological Activity
The IC50 for HDAC1 is 36 nM and the IC50 for HDAC2 is 47 nM
CAS Registry #
128517-07-7
Background
Romidepsin is a bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins. In vitro, romidepsin causes the accumulation of acetylated histones, and induces cell cycle arrest and apoptosis of some cancer cell lines with IC50 values in the nanomolar range.
References
1. McGraw AL. Am J Health Syst Pharm. 2013 Jul 1;70(13):1115-22.
2. Kim M, et al. Ann Pharmacother. 2012 Oct;46(10):1340-8.
3. Horwitz SM. Clin Adv Hematol Oncol. 2012 May;10(5):333-4.
4. VanderMolen, KM, et al. J. Antibiotics 2011: 64, 525-531.